<DOC>
	<DOCNO>NCT00209326</DOCNO>
	<brief_summary>• To determine effect four different single bolus dos FE200440 administer intravenously stop preterm labour compare placebo pregnant woman advance gestational age</brief_summary>
	<brief_title>A Proof Concept Study Assessing Effect Four Different Single Bolus Intravenous Doses FE200440 Placebo Stopping Preterm Labor</brief_title>
	<detailed_description>- To determine effect four different single bolus dos FE200440 administer intravenously stop preterm labour compare placebo pregnant woman advance gestational age - To establish effect four different single bolus dos FE200440 administer intravenously uterine contraction compare placebo - To evaluate effect four different single bolus dos FE200440 administer intravenously labour progression compare placebo - To establish dose-response curve single bolus dos FE200440 administer intravenously term time delivery , uterine contraction labour progression - To determine duration action four different single bolus dos FE200440 administer intravenously term time delivery , uterine contraction labour progression - To establish pharmacokinetic parameter FE200440 single bolus intravenous administration - To determine relation plasma concentration FE200440 uterine contraction labour progression - To compare maternal , fetal infant safety profile intravenous administration four different single bolus dos FE200440 placebo - To evaluate impact four different single bolus dos FE200440 administer intravenously delivery outcome , postpartum event lactation</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<criteria>1 . Signed Informed Consent Form , prior screen evaluation 2 . Mother fetus good general health 3 . Pregnant woman age ≥ 18 year 4 . Gestational age ( verify early ultrasound ultrasound available Last Menstrual Period ) 34 week + 0 day 35 week + 6 day ( day inclusive ) 5 . At randomisation , must 6 uterine contraction least 30 second duration 30 minute interval 6 . At randomisation , cervical length must ≤ 15 mm ( transvaginal ultrasound ) 7 . At randomisation , cervical dilatation must &gt; 1 cm &lt; 4 cm ( vaginal examination 1 . Contraindications mother fetus stop labour , include clinical suspicion abruptio placenta know suspected infection ( e.g . urinary tract infection , chorioamnionitis ) 2 . Controlled uncontrolled diabetes mellitus ( pregestational gestational ) 3 . Eclampsia severe preeclampsia current pregnancy 4 . Previous major uterine surgery ( e.g . myomectomy leiomyoma ) , congenital uterine abnormality , large leiomyoma , retain intrauterine device 5 . Rupture membrane current pregnancy 6 . Placenta praevia current pregnancy 7. ) 8 . Oligohydramnios polyhydramnios current pregnancy define amniotic fluid index ( AFI ) 7.2 cm 27.8 cm 9 . Fetal weight ( base ultrasound ) outside ± 2SD limit provide Appendix B 10 . Use cervical cerclage current pregnancy 11 . Current multiple pregnancy 12 . Fetal death utero previous current pregnancy 13 . Fetus know suspect abnormal karyotype major malformation current pregnancy 14 . Abnormal fetal heart rate Investigator judge reflect fetal distress 15 . Treatment nifedipine , nonsteroidal antiinflammatory agent ( NSAIDs ) intravenously administer magnesium sulphate contraction current pregnancy treatment betamimetics , atosiban progesterone within last 7 day prior randomisation 16 . Treatment anticoagulation fibrinolytic therapy prior screen , know suspect past history thromboembolic disorder 17 . Known , suspect past history hypocoagulability coagulation deficiency condition 18 . Known suspected hemoglobinopathy 19 . Use investigational drug current pregnancy 20 . Known , suspect past history ( last 12 month ) alcohol drug abuse 21 . Known hypersensitivity active ingredient excipients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>